Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Selumetinib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Status changed from active, no longer recruiting to completed.
- 20 May 2014 Planned primary completion date changed from 1 Apr 2014 to 1 Apr 2018, as per ClinicalTrials.gov record.